Eryaspase

Unassigned

New Medicines

ERYASP®, GRASPA® · Pancreatic cancer - second- line as add on to standard of care treatment

Information

ERYASP®, GRASPA®
New molecular entity
ERYtech Pharma
ERYtech Pharma

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Asparagine modulator
There are approximately 150,000 new cases of pancreatic cancer diagnosed each year in US and Europe. Pancreatic cancer has a five-year survival rate of < 10% and is one of the fastest growing cancer indications, and the 4th leading cause of cancer deaths in the US [1].
Pancreatic cancer - second- line as add on to standard of care treatment
Intravenous

ERYASP®, GRASPA® · Philadelphia-negative acute lymphoblastic leukaemia (ALL) in adults and children

Information

ERYASP®, GRASPA®
New molecular entity
ERYtech Pharma
Teva

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Jun 18: Erytech confirm that they have ceased development of eryaspase in the ALL indication, including withdrawing the EU MAA. They intend to focus development on solid tumours, including first-line pancreatic cancer and metastatic triple-negative breast cancer [9].

Category

Asparagine modulator
ALL is most common in children, adolescent and young adults, with 65% of cases diagnosed in people aged under 25 years. A second increase in incidence is observed in people aged over 60 years. In England, 536 people were diagnosed with ALL in 2011 and 202 people died from ALL in 2012. [3]
Philadelphia-negative acute lymphoblastic leukaemia (ALL) in adults and children
Intravenous

Further information

Yes
To be confirmed